ACM
LRMR icon

Asymmetry Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Asymmetry Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-34,943
Closed -$403K – 32
2021
Q3 		$403K Buy
+34,943
New +$419K 0.24% 29

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Asymmetry Capital Management's LRMR Position: Q4 2021 in Review

Asymmetry Capital Management sold out of Larimar Therapeutics (LRMR) in Q4 2021, closing a stake of 34,943 shares — an estimated $403K sold.

Asymmetry Capital Management first reported a position in LRMR in Q3 2021 and held it in 1 quarter. The position peaked at $403K in Q3 2021. 49 funds tracked by Wall St. Rank hold LRMR as of Q4 2021.

  • Asymmetry Capital Management reported no remaining Larimar Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Asymmetry Capital Management sold 34,943 Larimar Therapeutics shares in Q4 2021, an estimated $403K.
  • Asymmetry Capital Management first reported a position in Larimar Therapeutics in Q3 2021 and held it in 1 quarter.
  • Asymmetry Capital Management's Larimar Therapeutics position peaked at $403K in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2021.

Based on Asymmetry Capital Management's 13F filing for Q4 2021, filed 19 Jan 2022.